INTRODUCTION {#sec1-1}
============

The considerations for induction of anesthesia in patients undergoing cardiac surgery include hemodynamic stability, attenuation of the stress responses and maintenance of balance between myocardial oxygen demand and supply. Various intravenous (IV) inducing agents like thiopentone, etomidate, propofol and midazolam have been used for anesthetising these patients.\[[@ref1][@ref2][@ref3][@ref4][@ref5]\] Various authors have expressed concerns regarding induction of anesthesia with agents such as thiopentone, midazolam, ketamine.

Propofol and etomidate are well-known anesthetic agents routinely used for the induction of anesthesia for cardiac surgeries.\[[@ref6][@ref7][@ref8][@ref9][@ref10]\] The two drugs however have different induction characteristics.

Etomidate, first introduced in the seventies, was withdrawn, because of anaphylactic reactions to Cremaphore EL. There were also concerns about reductions in the serum cortisol levels,\[[@ref9][@ref11][@ref12]\] which lasts for up to 24 h. However, It has a very stable cardiovascular profile\[[@ref1][@ref13][@ref14]\] and has been reintroduced in India. Etomidate is recommended for induction in patients with poor left ventricular (LV) function. While, propofol may cause a reduction in systemic vascular resistance (SVR).

Hence, this study was conducted to compare the effect of anesthetic induction with single dose etomidate versus propofol on serum cortisol levels and hemodynamics.

MATERIALS AND METHODS {#sec1-2}
=====================

After obtaining Institutional Ethics Committee approval and written informed consent from the patients, 60 patients (age: 20--60 years, weight: 40--70 kg) of American Society of Anesthesiologists Grade II and III scheduled for elective coronary artery bypass grafting (CABG)/mitral valve replacement (MVR)/aortic valve replacement (AVR) on cardiopulmonary bypass (CPB) were enrolled in this prospective randomized study.

Patients undergoing emergency surgery, having congestive cardiac failure, renal dysfunction (serum creatinine \>2 mg/dl), on mechanical ventilation or on long-term steroid therapy, known adrenal or endocrine dysfunction were excluded from the study.

Proper preanesthetic check-up and all relevant investigations were done for all patients.

The patients were randomly divided into two groups of 30 patients each.

Propofol was chosen as other inducing agents like thiopentone and ketamine are not routinely used in MVR and CABG surgeries.

Group I: Injection propofol (P) group (2 mg/kg) IV.

Group II: Etomidate (E) group (0.2 mg/kg) IV.

Randomization was done by opening a sealed envelope just before entry to operating room.

In the operation theater, pulse oximeter, noninvasive blood pressure (BP) apparatus and five lead electrocardiogram (ECG) were connected to the patient.

Swan ganz catheter placement under local infiltration is done as routine in our Institution and to measure pre-induction values, i.v. Premedication in our Institution is done after the arrival of patient in OT. After peripheral IV cannulation and intra-arterial radial cannulation, central venous line and pulmonary artery/swan Ganz catheter placement under local infiltration, patient was premedicated with injection glycopyrrolate 0.2 mg IV, injection midazolam 2 mg, injection ranitidine 50 mg and injection ondansetron 4 mg.

After stabilization period of 5 min, the baseline values of heart rate, systolic and diastolic BP (SBP and DBP) (invasive BP), mean arterial pressure (MAP), central venous pressure (CVP), cardiac output (CO), cardiac index (CI), pulmonary capillary wedge pressure (PCWP), SVR, peripheral vascular resistance (PVR), SpO~2~, were recorded and ECG was monitored.

All patients were induced between 8 and 9 am and samples for baseline values of serum cortisol and blood sugar were obtained before induction.

Intravenous fentanyl 2 mcg/kg was given 3 min prior to induction.

After preoxygenation, Group I received 2 mg/kg propofol and Group II received 0.2 mg/kg etomidate for induction.

After the loss of eyelash reflex in both groups, again HR, SBP, DBP, MAP, CVP, PCWP, CO, CI, SVR, PVR were recorded. Injection vecuronium bromide 0.1 mg/kg IV was given, and endotracheal intubation was performed. Again the readings for HR, SBP, DBP, MAP, CVP, PCWP, CO, CI, PVR and SVR were recorded. Intraoperative analgesia was provided with injection fentanyl up to total dose of 20 mcg/kg as intermittent bolus doses. Anesthesia was maintained with isoflurane (0.2--2%) and injection 0.1 mg/kg vecuronium was administered as IV bolus followed by 0.02 mg/kg every 30--40 min. Femoral artery catheterization was done. Five min postintubation again HR, SBP, DBP, MAP, CVP, PCWP, CO, CI, SVR, PVR recorded. Patients received IV antibiotics after test dose and IV methylprednisolone 30 mg/kg in divided doses through central venous catheter.

Heparin in the dose of 300--400 units/kg was administered prior to initiation of CPB during CPB. Serum cortisol values and blood sugar levels were again measured while the patient was on CPB.

Heparin was reversed with protamine in the dose of 4.5 mg/kg after weaning the patient from CPB. Again serum cortisol and blood sugar were measured after heparin reversal.

At the end of surgery, patient was shifted to the cardiac ICU with an endotracheal tube *in situ* after adequate dose of muscle relaxant and opioid analgesic.

Patients were observed postoperatively for any adverse effects.

HR, IBP, NIBP, CVP, PCWP, CO, CI, SVR, PVR were recorded:

Baseline/before inductionAfter the induction (loss of eyelash reflex and verbal response)Immediately after intubationAfter 5 min of intubation.

Endocrine response {#sec2-1}
------------------

Serum cortisol values and blood sugar were measured at 4 time points:

Baseline before induction of anesthesiaDuring CPBAfter bypass/protamine reversal of heparin after termination of CPB andAt 24 h.

Data were summarized as the number (%) or mean ± standard deviation/median (range) as appropriate. Baseline categorical and continuous variables were compared between the groups using Fisher\'s exact test and Student\'s *t*-test respectively. Hemodynamic variables were compared between the groups using Student\'s *t*-test for independent samples. The primary outcome (serum cortisol and blood sugar) of the study was compared between the groups using Wilcoxon Rank Sum test since the data was non-normal. *P* \< 0.05 was considered as significant.

OBSERVATIONS AND RESULTS {#sec1-3}
========================

There was no significant difference in CO between both the groups though there was significant fall from baseline value in *P* group after induction \[Tables [1](#T1){ref-type="table"}--[12](#T12){ref-type="table"}\]. The values remained below baseline even 5 min after intubation which was significant. Baseline values were comparable in both the groups and no significant changes were observed in etomidate group after induction.

###### 

Patients characteristics and operation details

  Variable                     Group I (P) (*n*=30)   Group II (E) (*n*=30)   *P*
  ---------------------------- ---------------------- ----------------------- -------
  Age (years)                  33.96±10.88            36±12.33                0.499
  Sex (male/female)            15/15                  16/14                   
  Weight (kg)                  47.7±8.15              46.26±6.93              0.463
  Height (cm)                  161.1±7.7              162.8±8.3               0.414
  ASA Grade II                 22                     19                      
  ASA Grade III                8                      11                      
  Duration of surgery (in h)   5.25±1.11              5.4±1.02                0.587
  Surgical procedure                                                          
   MVR                         23                     22                      
   AVR                         4                      6                       
   CABG                        3                      2                       

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. ASA: American Society of Anesthesiologists, MVR: Mitral valve replacement, AVR: Aortic valve replacement, CABG: Coronary artery bypass grafting, SD: Standard deviation

###### 

Baseline hemodynamic parameters between the two groups

  Baseline parameters   Group I (*n*=30)   Group II (*n*=30)   *P*
  --------------------- ------------------ ------------------- -----------
  HR                    91.03±20.7         80.66±23.53         0.0714
  SBP                   117.63±15.66       111.56±16.005       0.143
  DBP                   73.93±11.41        72.5±8.16           0.586
  MAP                   88.38±12.01        85.08±10.50         0.2619
  CVP                   6.73±1.38          7.43±1.47           0.062
  PCWP                  6.63±1.65          8.86±1.19           \<0.001\*
  CO                    4.35±0.76          4.06±0.65           0.117
  CI                    2.41±0.42          2.26±0.38           0.15
  SVR                   1889.4±396.1       1798.4±310.21       0.32
  PVR                   141.66±30.4        155.4±30.3          0.08

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. HR: Heart rate, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, MAP: Mean arterial pressure, CVP: Central venous pressure, PCWP: Pulmonary capillary wedge pressure, CO: Cardiac output, CI: Cardiac index, SVR: Systemic vascular resistance, PVR: Peripheral vascular resistance, SD: Standard deviation

###### 

Hemodynamic responses between the two groups

                            Group I (P) (*n*=30)   Group II (E) (*n*=30)   *P*
  ------------------------- ---------------------- ----------------------- -----------
  HR                                                                       
   Baseline                 91.03±2.07             80.66±23.53             0.0714
   After induction          88.53±18.20            80.6±12.92              0.056
   After intubation         96.93±20.34            85.83±23.53             0.0501
   5 min after intubation   92.8±14.91             87.46±10.99             0.119
  SBP                                                                      
   Baseline                 117.63±15.66           111.56±16.005           0.143
   After induction          80.63±8.63             98.5±14.73              \<0.001\*
   After intubation         86.53±15.65            103.4±12.286            \<0.001\*
   5 min after induction    95.86±3.51             103.7±6.22              \<0.001\*
  DBP                                                                      
   Baseline                 73.93±11.41            72.53±8.16              0.586
   After induction          59.7±7.28              69.4±8.26               0.007\*
   After intubation         64.6±6.46              71.43±7.37              0.0015\*
   5 min after intubation   66.6±4.41              71.26±4.83              0.0003\*
  MAP                                                                      
   Baseline                 88.38±12.01            85.08±10.50             0.261
   After induction          67.97±5.79             80.54±9.39              \<0.001\*
   After intubation         72.79±5.54             82.07±7.09              \<0.001\*
   5 min after intubation   76.46±3.47             82.05±3.92              \<0.001\*

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. HR: Heart rate, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, MAP: Mean arterial pressure, SD: Standard deviation

###### 

CVP comparison between two groups

                           Group P (*n*=30)   Group E (*n*=30)   *P*
  ------------------------ ------------------ ------------------ --------
  Baseline                 6.73±1.38          7.43±1.47          0.062
  After induction          6.60±1.10          7.23±1.38          0.0554
  After intubation         7.86±0.93          7.4±1.24           0.109
  5 min after intubation   7.63±1.09          7.4±1.06           0.418

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. CVP: Central venous pressure, SD: Standard deviation

###### 

Pulmonary capillary wedge pressure

  PCWP                     Group P (*n*=30)   Group E (*n*=30)   *P*
  ------------------------ ------------------ ------------------ -----------
  Baseline                 7.43±1.38          9.06±1.57          \<0.001\*
  After induction          6.63±1.65          8.86±1.19          \<0.001\*
  After intubation         8.6±1.67           9.16±1.64          0.195
  5 min after intubation   8.76±1.13          9.06±1.25          0.38

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. PCWP: Pulmonary capillary wedge pressure, SD: Standard deviation

###### 

Cardiac output

  CO                       Group P (*n*=30)   Group E (*n*=30)   *P*
  ------------------------ ------------------ ------------------ -------
  Baseline                 4.35±0.76          4.06±0.65          0.117
  After induction          3.72±0.74          3.88±0.7           0.393
  After intubation         3.85±0.68          3.91±0.56          0.71
  5 min after intubation   3.87±0.60          3.8±0.5            0.625

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. CO: Cardiac output, SD: Standard deviation

###### 

Cardiac index

  CI                       Group P (*n*=30)   Group E (*n*=30)   *P*
  ------------------------ ------------------ ------------------ ------
  Baseline                 2.41±0.42          2.26±0.38          0.15
  After induction          2.06±0.41          2.15±0.32          0.38
  After intubation         2.13±0.37          2.17±0.31          0.65
  5 min after intubation   2.14±0.33          2.10±0.28          0.61

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. CI: Cardiac index, SD: Standard deviation

###### 

Systemic vascular resistance

                           Group P (*n*=30)   Group E (*n*=30)   *P*
  ------------------------ ------------------ ------------------ -----------
  Baseline                 1889.4±396.1       1798.4±310.21      0.32
  After induction          1587.267±123.53    1613.5±369.5       0.71
  After intubation         1822.56±130.011    1733.133±293.9     0.132
  5 min after intubation   1604.3±142.45      1920.2±259.09      \<0.001\*

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. SVR: Systemic vascular resistance, SD: Standard deviation

###### 

Pulmonary vascular resistance between two groups

                           Group P (*n*=30)   Group E (*n*=30)   *P*
  ------------------------ ------------------ ------------------ -------
  Baseline                 141.66±30.4        155.4±30.3         0.08
  After induction          125.46±25.12       138.5±25.9         0.052
  After intubation         140.5±21.48        147.8±16.65        0.146
  5 min after intubation   136.63±18.6        144.7±13.5         0.059

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. PVR: Pulmonary vascular resistance, SD: Standard deviation

###### 

Serum cortisol and blood glucose values between two groups

                                                      Group P (*n*=30)   Group E (*n*=30)   *P*
  --------------------------------------------------- ------------------ ------------------ -----------
  Serum cortisol values                                                                     
   Baseline/before induction                          11.7±1.95          12.2±2.94          0.44
   During bypass                                      14.8±1.62          9.36±3.04          \<0.001\*
   After bypass/after protamine reversal of heparin   23.26±3.14         7.66±2.91          \<0.001\*
   At 24 h postoperatively                            28.3±2.97          24.23±3.62         \<0.001\*
  Blood glucose levels                                                                      
   Baseline                                           97.43±15.66        93.83±15.9         0.380
   During bypass                                      158.03±38.62       138.53±33.5        0.041\*
   After protamine reversal/weaning off CPB           159.03±39.91       136.9±35.24        0.0265\*
   At 24 h postoperatively                            106.06±28.15       98.86±15.9         0.227

Values expressed as mean±SD. \**P*\<0.05 considered significant statistically. SD: Standard deviation, CPB: Cardiopulmonary bypass

###### 

Associated adverse outcomes between two groups

  Adverse reactions                                       Group P               Group E
  ------------------------------------------------------- --------------------- ----------------
  Postoperative nausea and vomiting                       None                  None
  Allergic reaction                                       None                  None
  Excitatory effects like myoclonus, dystocia or tremor   None                  None
  Adrenal depression                                      None                  None
  Pain on injection                                       None                  None
  Hypotension perioperatively                             None requiring        None requiring
  vasopressor support                                     vasopressor support   

###### 

Different doses of the two drugs used

  Drug                              Author                                 Dose (mg/kg)
  --------------------------------- -------------------------------------- --------------
  Propofol                          Patrick *et al.* (1985)^\[[@ref3]\]^   1.5
  Vermeyen *et al.*^\[[@ref16]\]^   1.5                                    
  Kaplan *et al.*^\[[@ref17]\]^     2.5                                    
  Boer *et al.*^\[[@ref7]\]^        2                                      
  Boer *et al.*^\[[@ref1]\]^        2                                      
  Singh *et al.*^\[[@ref4]\]^       1.5                                    
  Pandey *et al.*^\[[@ref11]\]^     2                                      
  Etomidate                         Gooding *et al.*^\[[@ref10]\]^         0.3
  Colvin *et al.*^\[[@ref13]\]^     0.3                                    
  Boer *et al.*^\[[@ref1]\]^        0.3                                    
  Yunqi *et al.*^\[[@ref18]\]^      0.3                                    
  Singh *et al.*^\[[@ref4]\]^       0.2                                    
  Morel *et al.*^\[[@ref19]\]^      0.3                                    
  Pandey *et al.*^\[[@ref11]\]^     0.2                                    
  Rahman *et al.*^\[[@ref15]\]^     0.2                                    

Unlike Group E, Group *P* showed significant fall in CI after induction which continued till 5 min after intubation as compared to baseline values.

Observations {#sec2-2}
------------

### Hemodynamic parameters {#sec3-1}

There was no significant difference in between the groups with respect to HR, CVP and PCWP. There was significant decrease in SBP, DBP and MAP between the groups after induction, after intubation and 5 min postintubation. There was significant decrease in CO and CI in propofol group when compared to baseline values after induction, after intubation and 5 min after intubation, but not in etomidate group. SVR was significantly decreased after induction in both the groups while the value continued to decrease at 5 min postintubation in the propofol group and increased significantly above baseline in the etomidate group. Values in PVR were significantly decreased after induction in both groups and increased to near baseline levels by 5 min postintubation.

### Myoclonus and hypotension {#sec3-2}

Myoclonus was not seen as the drug was injected slowly. hypotension occured post induction with propofol, it was defined as fall of MAP of more then 10% on the base line.

### Effects on serum cortisol levels {#sec3-3}

There was significant fall in the cortisol values in etomidate group during bypass and further significant fall after weaning off CPB as compared to the propofol group. The average cortisol value was reduced to approximately 50% at the time of weaning in etomidate group while it increased to almost double in the propofol group.

The serum cortisol level at 24 h was higher as compared to baseline values in both the groups. In the etomidate group, the serum cortisol returned to normal levels which were however almost twice the baseline values. In the propofol group, the serum levels remained high and were about two and a half times the baseline value.

### Effects on blood glucose levels {#sec3-4}

There was significant increase in blood glucose value during bypass and when weaning off CPB in both groups compared to baseline and between the two groups, but the rise was less in etomidate group due to decreased stress response because of inhibition of cortisol synthesis. After 24 h of surgery, however the values returned to baseline with no significant differences between the groups.

DISCUSSION {#sec1-4}
==========

The deleterious effects of anesthetic agents in patients suffering from coronary artery disease are well-known. Induction of general anesthesia may be a critical period during CABG and valve replacement surgery, especially in presence of LV dysfunction. There is a paucity of literature regarding the choice of suitable agent to avoid deleterious effects in such patients. Anesthetic induction techniques for cardiovascular surgery are based on considering hemodynamic stability and effects on myocardial oxygen supply and demand.

Various authors have concern regarding induction of anesthesia with agents such as etomidate, thiopentone, propofol, ketamine and midazolam. However, the use of etomidate and propofol has been considered superior to other IV anesthetic agents in these group of patients.\[[@ref5][@ref6][@ref7][@ref8][@ref9]\]

Selection of inducing agent {#sec2-3}
---------------------------

Etomidate (Lipuro. B Braun. Melsungen. Germany) is a short acting IV anesthetic agent used for the induction of general anesthesia. It was introduced as an IV agent in 1972 in Europe and in 1983 in United States. It has a rapid onset of action, a safe cardiovascular risk profile, and lack of histamine release and therefore is less likely to cause a significant drop in BP than other induction agents. It is an ideal induction agent for patients who are hemodynamically unstable. The normal adult serum cortisol levels are 5--25 mcg/dl. Etomidate suppresses corticosteroid synthesis in the adrenal cortex by reversibly inhibiting 11-beta-hydroxylase, an enzyme important in adrenal steroid production leading to primary adrenal suppression. The cortisol suppression induced by a single dose of etomidate is almost always limited to 24 h, and therefore does not pose any threat of prolonged adrenocortical suppression. The cortisol levels in our study also returned to normal levels at 24 h postinduction with etomidate.

Propofol is a short-acting, intravenously administered hypnotic agent. Propofol has been proposed to have several mechanisms of action, both through potentiation of GABA receptor activity, thereby slowing the channel-closing time, and also acting as a sodium channel blocker. Recent research has also suggested that the endocannabinoid system may contribute significantly to propofol\'s anesthetic action and to its unique properties. Propofol causes vasodilatation and may result in transient fall in systemic BP.

Various studies have shown stable cardiovascular profile of etomidate like studies by Gooding *et al*., Sun (1991), Yunqi *et al*., Hosten *et al*., Pandey *et al*. Some other authors have found propofol to be effective in patients with good LV function and combined with some analgesic as shown in the studies by Patrick *et al*., Stephan *et al*., Vermeyen *et al*., Kaplan *et al*.

Selection of dose for etomidate and propofol induction {#sec2-4}
------------------------------------------------------

Following authors have used different dosages of propofol and etomidate for induction in patients undergoing cardiovascular surgery \[[Table 12](#T12){ref-type="table"}\].

Based on above studies, we selected an induction dose of 2 mg/kg for propofol and 0.2 mg/kg for Etomidate for our study.

CONCLUSION {#sec1-5}
==========

Etomidate provides more stable hemodynamic parameters when used for induction of anesthesia as compared to propofol in patients with poor LV functionThere is a rise in serum Cortisol levels on the initiation of CPB after induction of anesthesia with propofol in our study. This was not present in the etomidate group, where the serum Cortisol levels reduced. Serum Cortisol levels returned to near normal range at 24 h without any untoward effects. The values though were almost twice the baseline\"Etomidate can therefore be safely used as an anesthetic induction agent in patients with poor LV function for CABG/MVR/AVR on CPB without serious cortisol suppression lasting more than 24 hNo untoward incidence was seen with either etomidate or propofol induction.
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